Objective: To study the expression of death receptor 6 (DR6) in esophageal cancer and the effect of cellular communication network factor 1 (CCN1) on the expression of DR6, and to find new molecular targets for the treatment of esophageal cancer. Methods: The expression of DR6 and CCN1 in esophageal cancer was analyzed by Real-Time PCR, immunohistochemistry and Western Blot. The effect of CCN1 on the expression of DR6 was analyzed by cell transfection experiment. Results: The expression of DR6 mRNA in esophageal cancer cell lines was higher than that in normal esophageal epithelial cells (P＜0.05). Western Blot and immunohistochemical analysis showed that DR6 and CCN1 were both expressed in esophageal carcinoma and increased in esophageal squamous cell carcinoma (P＜0.05). CCN1 up-regulated the protein expression of DR6 in esophageal squamous cell carcinoma and adenocarcinoma cell lines (P＜0.05). Conclusion: The expression of DR6 and CCN1 in esophageal squamous cell carcinoma is higher than that in normal epithelial cells, which may be involved in the occurrence and development of esophageal squamous cell carcinoma. CCN1 can affect the expression of DR6, which may affect the biological function of DR6.
WANG Pei
,
CHANG Zhiheng
,
CHAI Jianyuan
,
LIU Xiaofang
,
MA Huan
,
DANG Tong
. Expression of death receptor 6 in esophageal carcinoma and its relationship with CCN1[J]. Journal of Baotou Medical College, 2023
, 39(9)
: 79
-84
.
DOI: 10.16833/j.cnki.jbmc.2023.09.016
[1] Røsland GV,Engelsen AS. Novel points of attack for targeted cancer therapy[J].Basic Clin Pharmacol Toxicol,2015,116(1): 9-18.
[2] Lee YT,Tan YJ,Oon CE. Molecular targeted therapy: treating cancer with specificity[J].Eur J Pharmacol,2018,834: 188-196
[3] Medler J,Wajant H. Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target[J].Expert Opin Ther Targets,2019,23(4): 295-307.
[4] Dang T,Modak C,Meng X,Chai J,et al. CCN1 sensitizes esophageal cancer cells to TRAIL-mediated apoptosis[J].Exp Cell Res,2017,361(1): 163-169.
[5] Zhou N,Hofstetter WL.Prognostic and therapeutic molecular markers in the clinical management of esophageal cancer[J].Expert Rev Mol Diagn,2020,20(4): 401-411.
[6] Dang T,Chang Z,Meng J,et al. TNF antagonizes CCN1 in apoptosis in esophageal adenocarcinoma[J].Cytokine,2022,149: 155728.
[7] Takeuchi H,Miyata H,Gotoh M,et al. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database[J].Ann Surg,2014,260(2): 259-266.
[8] Elliott JA,Docherty NG,Eckhardt HG,et al. Weight loss,satiety,and the postprandial gut hormone response after esophagectomy: a prospective study[J].Ann Surg,2017,266(1): 82-90.
[9] Xu X,Lai Y,Hua ZC. Apoptosis and apoptotic body: disease message and therapeutic target potentials[J].Biosci Rep,2019,39(1): BSR20180992.
[10] King KL,Cidlowski JA. Cell cycle regulation and apoptosis[J].Annu Rev Physiol,1998,60: 601-617.
[11] Benschop R,Wei T,Na S. Tumor necrosis factor receptor superfamily member 21: TNFR-related death receptor-6,DR6[J].Adv Exp Med Biol,2009,647: 186-194.
[12] Pan G,Bauer JH,Dixit VM,et al. Identification and functional characterization of DR6,a novel death domain-containing TNF receptor[J].FEBS Lett,1998,431(3): 351-356.
[13] Stegmann S,Werner JM,Kuhl S,et al. Death receptor 6 (DR6) is overexpressed in astrocytomas[J].Anticancer Res,2019,39(5): 2299-2306.
[14] Yang K,Mooney C,Spahlinger G,et al. DR6 as a diagnostic and predictive biomarker in adult sarcoma[J].PLoS One,2012,7(5): e36525.
[15] Xie JJ,Xu LY,Xie YM,et al. Involvement of Cyr61 in the growth,invasiveness and adhesion of esophageal squamous cell carcinoma cells[J].Int J Mol Med.2011,27(3): 429,434.
